Valneva SE VALN
NASDAQ VALN
$6.91 -0.15 (-2.20%)
As of: Sep 4, 2026 · 3:14 PM EDT

Valneva SE (VALN) Non-Current Deffered Revenue (2022)

Valneva SE (VALN) posted Non-Current Deffered Revenue of $499908.4 for Q1 2026, down 0.59% sequentially from $502866.8 in Q4 2025, and down 87.33% YoY from $3.9 million in Q1 2025.

Analysis

Valneva SE (VALN) Non-Current Deffered Revenue (2022) Analysis & Trends

Valneva SE has reported Non-Current Deffered Revenue for 6 years, with the latest figure at $499908.4 in Q1 2026.

  • Quarterly Non-Current Deffered Revenue fell 87.33% year-over-year to $499908.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $499908.4 (down 87.33% YoY) and the FY2025 annual result came in at $502866.8, down 84.56% from the prior year.
  • Non-Current Deffered Revenue eased to $499908.4 in Q1 2026 per VALN's latest filing, from $502866.8 in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $137.5 million in Q1 2022 and troughed at -$5.3 million in Q4 2022.
  • A 5-year average of $19.5 million and a median of $5.7 million in 2024 frame the typical range for Non-Current Deffered Revenue.
  • The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue tumbled 198.59% in 2022, then soared 214.63% in 2023.
  • Over 5 years, Non-Current Deffered Revenue stood at -$5.3 million in 2022, then soared by 214.63% to $6.1 million in 2023, then slumped by 47.53% to $3.2 million in 2024, then tumbled by 84.37% to $502866.8 in 2025, then dropped by 0.59% to $499908.4 in 2026.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $499908.4, $502866.8, and $494510.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 138.43 Bn 130.58 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 63.34 Bn 58.15 Bn 1.37 Bn -
4 Moderna 57.98 Bn 52.85 Bn 52.00 Mn 147.00 Mn
5 Revolution Medicines 43.98 Bn 43.98 Bn - -
6 BeOne Medicines 39.92 Bn 34.82 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.42 Bn 32.11 Bn 992.69 Mn -
8 Royalty Pharma 28.42 Bn 27.58 Bn - -
9 Insmed 27.36 Bn 26.20 Bn 358.27 Mn -
10 Valneva SE 580.64 Mn 439.38 Mn 1.86 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 -5.35 Mn